Embody (joinem.co) advertises some of the lowest compounded GLP-1 prices anywhere — semaglutide from $79/month with a price-for-life pledge. Pallas Health's numbers are higher, and published differently: the whole arc — intro, renewal, interval — in one sentence, from a platform whose certification you can verify. That's the real shape of this comparison: a very low advertised number from a very young company, versus published terms you can check.
Pricing on both sides changes often — Embody's ad funnels show different numbers than its main site — so figures reflect its main site as published in August 2026. Confirm current numbers on both sites before signing up.
The three differences that matter most
- The advertised number. Embody's main site lists compounded semaglutide "starting at $79/month" and tirzepatide at $129/month, flat at every dose per its price-for-life pledge, with no membership and free 1–2 day shipping. Those numbers are lower than Pallas's — plainly. Pallas's compounded semaglutide injection is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Tirzepatide is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. With any deeply promotional price, confirm in writing what your renewal will be — Embody's own pledge is the right thing to hold it to.
- The paperwork. Embody's site currently gives two different cancellation notice windows — its refund policy says 72 hours before billing, its terms say 5 days before the end of your prescription period — and it advertises a satisfaction guarantee whose terms don't appear in its published refund policy. None of that makes the offer false; it does mean you should get the operative terms in writing before you pay. Pallas has one set of terms: cancel anytime, no notice window, nothing charged unless a clinician prescribes.
- Track record and tiers. Embody's operating entity started in late 2025 and offers compounded injections only. Pallas is also young (2026) — the difference is published clinical leadership and both tiers, with FDA-approved brands dispensed cash-pay from $499/month (the daily Wegovy® pill and Foundayo™; weekly pens $499 for the first month, then from $599/month).
About compounded medications
Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. A licensed clinician decides whether a compounded preparation — for example, a dose level or a formulation a brand-name product doesn't offer — is appropriate for you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Quick comparison
| Pallas Health | Embody | |
|---|---|---|
| Compounded semaglutide injection | Yes — one all-in price, renewal published | Yes — "starting at $79/mo" (main site; ad promos vary) |
| Compounded tirzepatide injection | Yes — one all-in price | Yes — "starting at $129/mo" |
| FDA-approved brand (Wegovy® pen and pill, Foundayo™, Zepbound®) | Yes — cash-pay from $499/mo | Not offered |
| Membership fee | None | None |
| Price changes as your dose increases | No — flat at every dose | No, per their price-for-life pledge |
| If a clinician doesn't prescribe | Nothing charged | Full refund |
| Refunds after medication is ordered | Cancel your plan anytime | Not refundable once ordered, per their policy |
| Cancellation notice | None — anytime, self-serve | Their refund policy says 72 hours; their terms say 5 days |
| States served | All 50 + DC | All states except Louisiana |
| Companion app | Free on iOS and Android, no subscription | Not offered |
| Operating since | 2026 | Late 2025 |
What Embody does well
The lowest main-site prices in the category. $79/month semaglutide and $129/month tirzepatide — flat at every dose per its pledge, with no membership and fast free shipping — undercut essentially every established platform, Pallas included. It refunds in full if a clinician doesn't prescribe, and it names its 503A compounding pharmacy partners on its site, a transparency point in its favor.
What Pallas does differently
Terms that match their marketing. One published price arc — $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. — one cancellation policy (anytime, no window), one billing rule (nothing charged until a clinician prescribes), no discrepancies to reconcile. What Pallas advertises is what its terms say. The compounded plans are compounded semaglutide and compounded tirzepatide injections, one price with clinician care included.
Both tiers. If a brand-name medication becomes the right fit, Pallas dispenses Wegovy®, Ozempic®, Zepbound®, and Mounjaro® cash-pay with no membership — Embody can't prescribe them at all.
Verifiability. Published clinical leadership, Louisiana and DC served, and a self-serve portal with anytime provider messaging plus the free Pallas companion app (iOS and Android). Whatever platform you consider, run the same checks: LegitScript status, clinician licensure in your state, US-licensed pharmacy sourcing — and the renewal price in writing.
Who should pick which
Embody may fit if:
- Its price is the deciding factor and you've confirmed the renewal rate and the operative cancellation terms in writing
- You only want compounded therapy and live outside Louisiana
Pallas is probably the better fit if:
- You want published, internally consistent terms and a verifiable certification
- You may want brand-name medication now or later
- You want cancel-anytime flexibility with no notice window and no order lock, and nothing charged unless a clinician prescribes
- You live in Louisiana or DC, or you'd use the free companion app
Switching between them
Bring your medication name, current dose, and titration history. Time an Embody exit around whichever notice window it confirms for you in writing. A Pallas clinician picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.
Bottom line: Embody's advertised prices are the lowest on the board, from a company operating since late 2025 with internally inconsistent cancellation terms and a guarantee whose conditions aren't published. Pallas costs more per month and publishes everything: the full price arc, one cancellation policy, nothing charged until a clinician prescribes, brand-name access, and certification you can verify. If price alone decides it, hold Embody to its pledge in writing; if published terms decide it, that's what Pallas is built on.
